However, this antigen-specific effect may be limited to CD8 + T cells because of the low expression of MHC Class II by MDSC – a theory supported by the inhibitory effects of tumor-associated MDSC on CD8+ T cells demonstrated in human cells in vitro and mouse models, which can be reversed by anti-MDSC host directed therapies (127, 128). The gene discussed is CD8A; the disease is neoplasm.